Merck & Co. stock: HIV Glasgow adds pipeline milestones

Merck & Co. stock traded at 131.56 euros on Lang & Schwarz at 16:33 CET on Monday, November 9, 2026, 0.20 percent below the Xetra close of Friday, November 6. The company is putting new HIV treatment and prevention data at the center of its near-term pipeline agenda as HIV Drug Therapy Glasgow 2026 runs through Wednesday.

HIV pipeline broadens treatment choices

In a Merck announcement dated November 2, the drugmaker said the Glasgow program would include Phase 3 subgroup analyses and patient-reported outcomes for IDVYNSO and the investigational once-weekly combination of islatravir and lenacapavir.

The program also covers once-weekly islatravir and ulonivirine, as well as alimatravir, an investigational once-monthly oral pre-exposure prophylaxis. Merck said adult enrollment is complete in both ongoing Phase 3 alimatravir trials, a step that moves the prevention program toward later clinical milestones.

Regulatory dates sharpen the outlook

The U.S. Food and Drug Administration has accepted two supplemental applications for IDVYNSO. The applications cover treatment-naive adults and 96-week data in virologically suppressed adults, with a target action date of April 22, 2027.

For investors, the HIV update adds another execution point to Merck's effort to broaden growth beyond its established oncology franchise. The commercial opportunity remains dependent on clinical results, regulatory decisions and eventual adoption; pipeline progress does not guarantee approval or sales.

Merck's latest global pipeline milestones are also being followed across the market report.

U.S. healthcare shares remain linked to the wider S&P 500 market environment.

More news and analyses on Merck & Co. stock.